Comparative Pharmacology
Head-to-head clinical analysis: PREGABALIN versus VIMPAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREGABALIN versus VIMPAT.
PREGABALIN vs VIMPAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the alpha2-delta subunit of voltage-gated calcium channels, reducing calcium influx and decreasing release of excitatory neurotransmitters (e.g., glutamate, norepinephrine, substance P).
Selective enhancement of slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing.
Initial: 75 mg orally twice daily; may increase to 150 mg twice daily within 1 week; maximum: 600 mg/day in divided doses.
Adults: 200 mg oral or IV as a loading dose, followed by 100 mg twice daily (200 mg/day) starting the day after loading. May increase by 50 mg twice daily every week up to 200 mg twice daily (400 mg/day).
None Documented
None Documented
Clinical Note
moderatePregabalin + Fluticasone propionate
"The therapeutic efficacy of Fluticasone propionate can be increased when used in combination with Pregabalin."
Clinical Note
moderatePregabalin + Haloperidol
"The therapeutic efficacy of Haloperidol can be increased when used in combination with Pregabalin."
Clinical Note
moderatePregabalin + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Pregabalin."
Clinical Note
moderatePregabalin + Fluconazole
Terminal elimination half-life is approximately 6.3 hours. In patients with renal impairment, half-life is prolonged (up to 48 hours in anuria). Requires dose adjustment based on creatinine clearance.
Terminal half-life: 13-16 hours (mean ~13 h at steady state); prolonged with renal impairment (CrCl <30 mL/min: ~22 h) and in patients with hepatic impairment (Child-Pugh B: ~17 h; Child-Pugh C: ~22 h).
Primarily renal excretion as unchanged drug (92-99% of dose). Approximately 0.1% is metabolized. No biliary or fecal elimination of significance.
Renal: ~95% (40% as parent drug, 39% as O-desmethyl metabolite, and ~15% as other minor metabolites); minimal biliary/fecal elimination (less than 1%).
Category A/B
Category C
Anticonvulsant
Anticonvulsant
"The serum concentration of Fluconazole can be increased when it is combined with Pregabalin."